222 related articles for article (PubMed ID: 36217728)
1. Fibrinolytic Changes in Women with Preeclampsia.
Godtfredsen AC; Sidelmann JJ; Dolleris BB; Jørgensen JS; Johansen EKJ; Pedersen MFB; Palarasah Y; Gram JB
Clin Appl Thromb Hemost; 2022; 28():10760296221126172. PubMed ID: 36217728
[TBL] [Abstract][Full Text] [Related]
2. [Relationship between plasma levels of thrombin activatable fibrinolysis inhibitor, plasminogen activator inhibitor-1 and tissue-type plasminogen activator and deep venous thrombosis in patients with systemic lupus erythematosus].
Liu YF; Hou N; Shi YJ; Li CX; Gao YJ; Liu LN
Zhonghua Yi Xue Za Zhi; 2023 Jun; 103(21):1638-1642. PubMed ID: 37248064
[No Abstract] [Full Text] [Related]
3. Fibrinolysis parameters in Sudanese women with severe preeclampsia.
Elzein HO; Muddathir AR; Rida M; Rayis DA; Elhassan EM; Adam I
Hypertens Pregnancy; 2016 Nov; 35(4):559-564. PubMed ID: 27598010
[TBL] [Abstract][Full Text] [Related]
4. Fibrin lysability is associated with central obesity and inflammation in women with polycystic ovary syndrome.
Godtfredsen ACM; Sidelmann JJ; Gram JB; Andersen M; Glintborg D
Acta Obstet Gynecol Scand; 2020 Aug; 99(8):1078-1084. PubMed ID: 32048272
[TBL] [Abstract][Full Text] [Related]
5. The suboptimal fibrinolytic response in COVID-19 is dictated by high PAI-1.
Whyte CS; Simpson M; Morrow GB; Wallace CA; Mentzer AJ; Knight JC; Shapiro S; Curry N; Bagot CN; Watson H; Cooper JG; Mutch NJ
J Thromb Haemost; 2022 Oct; 20(10):2394-2406. PubMed ID: 35780481
[TBL] [Abstract][Full Text] [Related]
6. Venous thrombosis risk associated with plasma hypofibrinolysis is explained by elevated plasma levels of TAFI and PAI-1.
Meltzer ME; Lisman T; de Groot PG; Meijers JC; le Cessie S; Doggen CJ; Rosendaal FR
Blood; 2010 Jul; 116(1):113-21. PubMed ID: 20385790
[TBL] [Abstract][Full Text] [Related]
7. Fibrinolysis inhibitors in plaque stability: a morphological association of PAI-1 and TAFI in advanced carotid plaque.
Jönsson Rylander AC; Lindgren A; Deinum J; Bergström GM; Böttcher G; Kalies I; Wåhlander K
J Thromb Haemost; 2017 Apr; 15(4):758-769. PubMed ID: 28135035
[TBL] [Abstract][Full Text] [Related]
8. Variations in fibrinolytic parameters and inhibin-A in pregnancy: related hypertensive disorders.
Sartori MT; Serena A; Saggiorato G; Campei S; Faggian D; Pagnan A; Paternoster DM
J Thromb Haemost; 2008 Feb; 6(2):352-8. PubMed ID: 18021302
[TBL] [Abstract][Full Text] [Related]
9. Coagulofibrinolytic changes in patients with disseminated intravascular coagulation associated with post-cardiac arrest syndrome--fibrinolytic shutdown and insufficient activation of fibrinolysis lead to organ dysfunction.
Wada T; Gando S; Mizugaki A; Yanagida Y; Jesmin S; Yokota H; Ieko M
Thromb Res; 2013 Jul; 132(1):e64-9. PubMed ID: 23726093
[TBL] [Abstract][Full Text] [Related]
10. Variable Resistance to Plasminogen Activator Initiated Fibrinolysis for Intermediate-Risk Pulmonary Embolism.
Stubblefield WB; Alves NJ; Rondina MT; Kline JA
PLoS One; 2016; 11(2):e0148747. PubMed ID: 26866684
[TBL] [Abstract][Full Text] [Related]
11. Physical activity status and adverse age-related differences in coagulation and fibrinolytic factors in women.
DeSouza CA; Jones PP; Seals DR
Arterioscler Thromb Vasc Biol; 1998 Mar; 18(3):362-8. PubMed ID: 9514404
[TBL] [Abstract][Full Text] [Related]
12. Recognition of Plasminogen Activator Inhibitor Type 1 as the Primary Regulator of Fibrinolysis.
Urano T; Suzuki Y; Iwaki T; Sano H; Honkura N; Castellino FJ
Curr Drug Targets; 2019; 20(16):1695-1701. PubMed ID: 31309890
[TBL] [Abstract][Full Text] [Related]
13. Prolonged duration of type 2 diabetes is associated with increased thrombin generation, prothrombotic fibrin clot phenotype and impaired fibrinolysis.
Konieczynska M; Fil K; Bazanek M; Undas A
Thromb Haemost; 2014 Apr; 111(4):685-93. PubMed ID: 24306139
[TBL] [Abstract][Full Text] [Related]
14. Fibrinolysis during normal human pregnancy: complex inter-relationships between plasma levels of tissue plasminogen activator and inhibitors and the euglobulin clot lysis time.
Wright JG; Cooper P; Astedt B; Lecander I; Wilde JT; Preston FE; Greaves M
Br J Haematol; 1988 Jun; 69(2):253-8. PubMed ID: 3134043
[TBL] [Abstract][Full Text] [Related]
15. Increased plasminogen activator inhibitor-1, decreased tissue factor pathway inhibitor, and unchanged thrombin-activatable fibrinolysis inhibitor levels in patients with primary hyperparathyroidism.
Erem C; Kocak M; Nuhoglu I; Yilmaz M; Ucuncu O
Eur J Endocrinol; 2009 May; 160(5):863-8. PubMed ID: 19233920
[TBL] [Abstract][Full Text] [Related]
16. Reduced fibrinolytic resistance in patients with factor XI deficiency. Evidence of a thrombin-independent impairment of the thrombin-activatable fibrinolysis inhibitor pathway.
Colucci M; Incampo F; Cannavò A; Menegatti M; Siboni SM; Zaccaria F; Semeraro N; Peyvandi F
J Thromb Haemost; 2016 Aug; 14(8):1603-14. PubMed ID: 27094709
[TBL] [Abstract][Full Text] [Related]
17. Assessment of plasminogen activator inhibitor-1(PAI1) and thrombin activitable fibrinolysis inhibitor (TAFI) in Egyptian children with hemophilia A.
Soliman M; Osman N; Hefnawy S; El Hawy MA
Pediatr Hematol Oncol; 2022 May; 39(4):318-328. PubMed ID: 34668834
[TBL] [Abstract][Full Text] [Related]
18. Plasminogen activators (t-PA and u-PA) and plasminogen activators inhibitors (PAI-1 and PAI-2) in some myeloproliferative syndromes.
Rość D; Kremplewska-Nalezyta E; Gadomska G; Zastawna E; Michalski A; Drewniak W
Med Sci Monit; 2000; 6(4):684-91. PubMed ID: 11208392
[TBL] [Abstract][Full Text] [Related]
19. Haemostatic factors in women with history of preeclampsia.
Portelinha A; Cerdeira AS; Belo L; Braga J; Tejera E; Pinto A; Pinto F; Areias MJ; Patrício B; Rebelo I
Thromb Res; 2009 May; 124(1):52-6. PubMed ID: 19049844
[TBL] [Abstract][Full Text] [Related]
20. An inhibitor of activated thrombin-activatable fibrinolysis inhibitor potentiates tissue-type plasminogen activator-induced thrombolysis in a rabbit jugular vein thrombolysis model.
Nagashima M; Werner M; Wang M; Zhao L; Light DR; Pagila R; Morser J; Verhallen P
Thromb Res; 2000 May; 98(4):333-42. PubMed ID: 10822080
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]